77 related articles for article (PubMed ID: 23198869)
1. Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly.
Matsumoto T; Yokota K; Sawada M; Sakakibara A; Shibata S; Yasue S; Tomita Y; Yatsuya H; Akiyama M
J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1514-20. PubMed ID: 23198869
[TBL] [Abstract][Full Text] [Related]
2. Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
Umeda T; Aoki K; Yokoyama A; Ohara H; Hayashi O; Tanaka K; Nishioka K
J Dermatol; 1998 Sep; 25(9):569-72. PubMed ID: 9798342
[TBL] [Abstract][Full Text] [Related]
3. [Chemotherapy of malignant melanoma].
Ishihara K
Gan To Kagaku Ryoho; 1995 Jan; 22(1):23-7. PubMed ID: 7529980
[TBL] [Abstract][Full Text] [Related]
4. Local injection of interferon beta in malignant melanoma of the esophagus as adjuvant of systemic pre- and postoperative DAV chemotherapy: case report with 7 years of long-term survival.
Kawada K; Kawano T; Nagai K; Nishikage T; Nakajima Y; Tokairin Y; Ogiya K; Tanaka K; Iwai T
Gastrointest Endosc; 2007 Aug; 66(2):408-10. PubMed ID: 17643724
[No Abstract] [Full Text] [Related]
5. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
6. Sequential local injection of low-dose interferon-beta for maintenance therapy in stage II and III melanoma: a single-institution matched case-control study.
Aoyagi S; Hata H; Homma E; Shimizu H
Oncology; 2012; 82(3):139-46. PubMed ID: 22433252
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy with low-dose interferon-beta for stage II and III melanoma: results of a retrospective analysis.
Yanagi T; Hata H; Homma E; Kitamura S; Imafuku K; Shimizu H
Clin Exp Dermatol; 2017 Oct; 42(7):781-785. PubMed ID: 28649738
[TBL] [Abstract][Full Text] [Related]
8. [New combination chemotherapy for malignant melanoma--PAV(peplomycin, ACNU, VCR) therapy].
Ikeda S; Tajima K; Miyasato H; Terakado T; Suzuki T; Miura T
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2198-204. PubMed ID: 6194756
[TBL] [Abstract][Full Text] [Related]
9. Therapy-related myelodysplastic syndrome developed by dacarbazine, nimustine hydrochloride and vincristine sulfate (DAV) therapy for patient with malignant melanoma.
Nitta Y; Ikeya T; Sakakibara A; Tomita Y
J Dermatol; 2011 Feb; 38(2):164-8. PubMed ID: 21269313
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy of malignant melanoma].
Ishihara K; Yamazaki N; Asano K
Gan To Kagaku Ryoho; 1993 Aug; 20(10):1287-92. PubMed ID: 7688498
[TBL] [Abstract][Full Text] [Related]
11. [Malignant melanoma in Japan: unique distribution and effect of DAV chemoimmunotherapy (part II)].
Ishihara K; Hayasaka K; Ikeda S; Terakado T; Kukita A; Seki Y; Jimbow K; Suzuki M
Gan To Kagaku Ryoho; 1984 Mar; 11(3):467-73. PubMed ID: 6703721
[TBL] [Abstract][Full Text] [Related]
12. The use of DAV (DTIC, ACNU and VCR) and natural interferon-beta combination therapy in malignant melanoma.
Nagatani T; Ichiyama S; Onuma R; Miyazawa M; Matsuzaki T; Miyagawa K; Baba N; Uchiyama M; Nakajima H
Acta Derm Venereol; 1995 Nov; 75(6):494. PubMed ID: 8651034
[No Abstract] [Full Text] [Related]
13. [Case of metastatic malignant melanoma responded to combination chemotherapy with DTIC].
Tamura T; Miyamoto H; Harada M; Makinoya T; Yamamoto M; Miyoshi Y; Komi N
Gan To Kagaku Ryoho; 1984 Feb; 11(2):327-32. PubMed ID: 6582806
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
15. [Malignant melanoma in Japan: unique distribution and effect of DAV chemoimmunotherapy].
Jimbow K; Takahashi H; Ishihara K; Hayasaka K; Kukita A; Seki Y; Ikeda S; Terakado T
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1942-9. PubMed ID: 7184382
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
Stadler R; Luger T; Bieber T; Köhler U; Linse R; Technau K; Schubert R; Schroth K; Vakilzadeh F; Volkenandt M; Gollnick H; Von Eick H; Thoren F; Strannegård O
Acta Oncol; 2006; 45(4):389-99. PubMed ID: 16760174
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
18. [Malignant melanoma].
Matsumoto K; Saida T
Nihon Rinsho; 2006 Jul; 64(7):1321-6. PubMed ID: 16838651
[TBL] [Abstract][Full Text] [Related]
19. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
20. [Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls].
Beiteke U; Ruppert P; Garbe C; Oxenfarth R; Kastl I; Türker T; Tronnier H; Frosch PJ
Hautarzt; 1993 Jun; 44(6):365-71. PubMed ID: 8335459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
